8 Best Peptides for Gum Disease

What to Know Before Choosing a Peptide for Gum Disease

Gum disease sits at the intersection of bacterial infection, immune dysregulation, and tissue destruction, which means the peptides people reach for here are doing very different jobs. Some are antimicrobial, designed to disrupt the bacterial biofilms that drive the condition. Others are anti-inflammatory, working to interrupt the immune cascade that causes the actual bone and tissue loss. A third category focuses on regeneration, trying to rebuild what the disease has already damaged. Many protocols combine compounds from more than one category.

Every compound in this guide earned its place the same way: people use it or are actively discussing using it for gum disease. That is the whole test. FDA approval, trial data depth, and regulatory status were not used as filters. The field here runs from an FDA-cleared surgical tool already used in periodontal operating rooms to a tripeptide discussed almost entirely in community forums. Both belong on this list, and both carry an honest description of exactly where their evidence stands. A thin evidence base is described plainly inside each entry, not used as a reason to exclude a compound.

The numbers in front of each entry are a spine for the list, not a verdict. The order reflects how prominently each compound appears in research and documented real-world use, not a recommendation that one compound is better than another for you. A compound that appears later might be the more relevant one depending on whether your priority is bacterial control, inflammation management, or tissue repair. The personalized decision belongs in the app, not in a listicle.

1. AMY-101: The Strongest Human Trial Data for Gingivitis

AMY-101 is a synthetic cyclic peptide developed by Amyndas Pharmaceuticals, and it currently holds the most compelling human clinical evidence of any peptide specifically tested for gum disease. To understand what it does, it helps to understand a particular trick that the primary periodontal pathogen, Porphyromonas gingivalis, uses to survive. This bacterium produces enzymes called gingipains that hijack the complement cascade, the branch of the immune system responsible for tagging and destroying bacterial invaders. By cleaving complement components at the C3, C4, and C5 levels, P. gingivalis causes a signaling molecule called C5a to accumulate locally. That buildup drives destructive inflammation while simultaneously helping the bacteria evade immune clearance, a two-sided mechanism that makes conventional treatment difficult. AMY-101 blocks the cascade at C3, cutting off the entire downstream reaction before C5a can accumulate.

In a Phase 2 randomized placebo-controlled trial involving 39 people with gingivitis and early periodontitis, AMY-101 was administered locally once a week for three weeks. Inflammation resolved within 21 days, and that benefit held for 90 days after treatment without any mechanical scaling or root planing. That last detail matters: standard periodontal care almost always requires physical removal of calculus and plaque from below the gumline, so a peptide achieving resolution through the immune pathway alone is a meaningful finding, at least in the gingivitis range of the disease.

AMY-101 is not commercially available. It completed Phase 2 and the company is pursuing a path to Phase 3 trials with the FDA. It exists right now only within clinical trial settings, so anyone who encounters it outside a registered study should exercise real caution. Its position at the top of this list reflects the quality of its evidence rather than its accessibility, and it is worth knowing the name as the field moves toward potential approval.

2. KSL-W: An Antimicrobial Peptide With Confirmed Human Safety

KSL-W, also referred to as P4M01 in pipeline documentation, is an antimicrobial peptide developed by P4 Microbiome and delivered in an unusual format: a chewing gum. The antimicrobial peptide chewing gum formulation is designed to release the compound directly in the oral environment where periodontal pathogens live, rather than requiring topical application by a clinician.

The clinical record here is more substantial than most peptides in this space. A combined Phase 1/2a trial established the safety profile and confirmed that doses of 20 milligrams or more reduced plaque and gingival inflammation, with 30 milligrams producing the strongest effects and no severe adverse events reported across the cohort. A separate Phase 2 double-blind randomized trial using a four-day plaque regrowth model confirmed the compound was effective against dental plaque formation and safe for human use even without other oral hygiene methods alongside it. No significant adverse events, serious adverse events, or deaths were reported in either study.

KSL-W works as a direct antimicrobial agent targeting the bacterial biofilm that drives periodontal inflammation, reducing the load of pathogens like Streptococcus and Porphyromonas species that colonize the gingival sulcus. Phase 2 for periodontal disease is listed as completed in the company's pipeline, but like AMY-101, this compound is not yet commercially available and is not FDA-approved. Its entry in this guide is warranted by legitimate human safety and efficacy data, not by current accessibility.

3. P-113: A Salivary Protein Fragment Studied as an Oral Spray

P-113 is a 12-amino acid antimicrobial peptide derived from histatin 5, a protein that occurs naturally in human saliva. The logic behind it is straightforward: saliva already contains peptides that inhibit periodontal pathogens, and P-113 concentrates the most active fragment of one of those natural compounds into a deliverable format. Nal-P-113 is a modified version with improved stability and antimicrobial activity compared to the parent fragment.

In a clinical study involving 28 participants, P-113 administered as an oral spray over four weeks produced significant reductions in Streptococcus and Porphyromonas species, the two bacterial genera most directly tied to early and advanced periodontal disease. Plaque weight decreased and gingival index scores improved across the treatment group. In animal models, P-113 reduced bacterial load and lowered levels of interleukin-1 beta and TNF-alpha, two key inflammatory proteins elevated in active periodontal disease. One competitive analysis of antimicrobial peptides ranked it as the most potent for biofilm disruption among the compounds studied.

P-113 is at the clinical study stage and is not widely available for independent use. Specialized dental prescriptions may become an avenue as development progresses, but no approval has been granted. The oral spray delivery format is notable because it places the compound directly at the site of bacterial activity without requiring injection or surgical access, which may shape how it eventually reaches patients if it completes the regulatory pathway.

4. EMD / Emdogain: The FDA-Cleared Standard for Periodontal Regeneration

Emdogain is the outlier on this list: already in clinical use, already FDA-cleared, and already part of standard periodontal surgery in the hands of periodontists worldwide. It contains enamel matrix derivative, which is primarily the protein amelogenin. What makes it relevant here is that amelogenin is a peptide-based signal, and the mechanism is fundamentally a peptide mechanism.

During normal tooth development, amelogenin proteins guide the formation of cementum, the periodontal ligament, and the alveolar bone that anchors the tooth in the jaw. Emdogain works by delivering this developmental signal to a surgically exposed root surface, prompting periodontal ligament cells to regenerate the attachment apparatus that periodontitis destroys. Multiple randomized clinical trials have established its effectiveness for regeneration in infrabony defects, the pockets of bone loss below the gumline that represent advanced disease. ABM/P-15, another regenerative peptide scaffold applied in a similar surgical context, has also been confirmed in randomized clinical trials as beneficial for periodontal regeneration in infrabony defects.

Emdogain is applied by dental professionals during surgery. It is not an over-the-counter product and is not something a patient administers independently. Its presence here acknowledges that the most evidentially established peptide intervention for periodontal tissue loss is already a clinical reality, even if most people searching for the best peptides for gum disease have never heard of it by name.

5. BPC-157: The Most Discussed Compound in Community Protocols

BPC-157 is a synthetic 15-amino acid peptide originally derived from a protein found in gastric juice, and it is the most frequently cited compound in community discussions about gum disease by a wide margin. On Reddit communities dedicated to periodontal health and peptide use, it appears in thread after thread, often combined with Thymosin Beta-4, and the reported experiences are consistent enough to form a recognizable pattern: reduced bleeding and gum irritation within days, meaningful inflammation control over weeks, and significant dispute about whether any tissue regrowth actually occurs.

No large-scale human clinical trial has been published for BPC-157 in gum disease or periodontal applications as of 2026. What exists is a combination of animal research showing wound healing acceleration, fibroblast stimulation, and angiogenesis support, alongside a substantial volume of user-reported experience from people applying it to oral tissue inflammation. Functional medicine practitioners sometimes suggest it for oral mucosal repair alongside standard dental care, particularly for reducing the inflammatory component of active periodontal disease.

The distinction that community users and practitioners both emphasize is the difference between healing inflamed gums and reversing recession. Inflammation control is widely reported; gum tissue regrowth to reverse existing recession is contested, with most accounts noting no measurable change in gum height despite reduced bleeding and pain. The dental consensus reflected in community threads is that reversing recession without surgery is not achievable with current peptides, including BPC-157. Users who describe injecting directly near affected gum tissue report the strongest effects, while at least one dentist has noted that oral capsule administration does not appear to reach gum tissue effectively. This is user-reported experience, not a controlled trial, and it carries all the limitations that implies.

6. GHK-Cu: For Slowing the Tissue Destruction Process

GHK-Cu is a naturally occurring tripeptide, glycine-histidine-lysine bound to a copper ion, found in human blood plasma and connective tissue. It is best known in the context of skin biology and wound healing, where its role in tissue remodeling, collagen synthesis modulation, and anti-inflammatory signaling is supported by published research. In the gum disease context, the conversation around GHK-Cu focuses on a related but distinct mechanism: its proposed ability to downregulate matrix metalloproteinase-8.

Matrix metalloproteinase-8, or MMP-8, is an enzyme that degrades collagen in the extracellular matrix of gum tissue. It is one of the key destructive mediators elevated in active periodontitis, and reducing its activity is a legitimate therapeutic target. The claim that GHK-Cu downregulates MMP-8 in gum tissue is the main rationale cited in community use, though the human clinical evidence specifically for gum disease applications is limited as of 2026. Most of what underlies this claim comes from GHK-Cu's broader tissue remodeling research rather than dental-specific trials.

In community forums, users describe gums feeling noticeably healthier and teeth feeling cleaner after using GHK-Cu, with MMP-8 downregulation cited as the likely explanation for managing disease progression. It is available commercially as a topical ingredient and as a research chemical, making it more accessible than most compounds on this list. The framing from people who use it for gum disease tends toward disease management and progression slowing rather than reversal of existing damage, which aligns with what the broader research on this compound reasonably supports.

7. KPV: For the Inflammatory Pain Component

KPV is a tripeptide made of three amino acids: lysine, proline, and valine. It is derived from the C-terminal end of alpha-melanocyte-stimulating hormone, a peptide with well-established anti-inflammatory and immunomodulatory properties. KPV retains the anti-inflammatory core activity of the parent molecule in a much smaller and more deliverable format. It is not an antimicrobial and not a tissue regenerator in the way BPC-157 or Emdogain are. Its primary role in gum disease protocols is pain and inflammation management.

In the gum disease context, KPV is almost always discussed alongside BPC-157 and TB-500 as part of combination protocols. Its specific role, as reported in community forums, is relief from gum-related pain and reduction of inflammatory discomfort. One community user reported that daily KPV use over a year stopped chronic gum pain that had persisted through other interventions. The evidence here is experiential rather than clinical: no dedicated human trial data exists for KPV in periodontal disease as of 2026, and the compound is used as a research chemical rather than a prescribed therapy for this application.

The anti-inflammatory cytokine modulation associated with KPV is biologically relevant to gum disease because active periodontitis involves elevated TNF-alpha, IL-6, and IL-1 beta, the same inflammatory signaling proteins that KPV is thought to modulate through pathways derived from alpha-MSH activity. That biological logic supports its use in this category even without gum-specific trials. People working through community protocols who find BPC-157 alone insufficient for pain management are the population most likely to add KPV, and that is precisely the use pattern reflected in the available community reporting.

8. TB-500: The Standard Pairing for Tissue Repair Protocols

TB-500 is a synthetic analog of Thymosin Beta-4, a naturally occurring peptide involved in cell migration, tissue repair, and the regulation of actin, the structural protein that forms much of a cell's internal scaffolding. Think of actin as the framework that allows cells to move toward damaged tissue and begin repair; Thymosin Beta-4 and by extension TB-500 facilitates that movement. In the gum disease context, TB-500 is almost never discussed as a standalone intervention. It is the near-universal pairing to BPC-157 in community protocols, with users reporting that the combination produces stronger anti-inflammatory and tissue-repair results than either compound alone.

The evidence for TB-500 specifically in gum disease or periodontal applications is user-reported. No published human clinical trial has examined it for this use as of 2026. The rationale for its inclusion in oral tissue protocols draws from its broader tissue repair and anti-inflammatory research, applied to the gum environment. Community reports suggest it helps prevent disease progression and reduces the inflammatory burden, though the same limitations apply here as to BPC-157: recession reversal is not a consistently reported outcome, and the compound exists in a research-chemical category without regulatory approval for dental use.

What distinguishes TB-500 from KPV as a pairing to BPC-157 is the mechanism emphasis. KPV is chosen for pain and cytokine modulation. TB-500 is chosen for its tissue repair and cell migration properties. Someone running a combination protocol for active gum disease is typically layering compounds to address inflammation and structural repair together, and TB-500 is the tissue-repair layer in that logic. That combination context is what places it on this list.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides available without a prescription?

It depends on the compound. Emdogain is applied by a dental professional during surgery and is not a consumer product. AMY-101 and KSL-W are not commercially available at all as of 2026 and exist only within clinical trial settings. BPC-157, GHK-Cu, KPV, and TB-500 are available as research chemicals through gray-market suppliers, which means they are sold without FDA approval for human therapeutic use and carry real risks of contamination, mislabeling, and unknown long-term effects. The risk profile for locally applied oral peptides is generally considered lower than for systemic injectable use, but none of the research-chemical options have been approved for gum disease applications.

Can peptides actually regrow receding gums?

The honest answer is that the evidence for true gum regrowth without surgery is weak across all the compounds discussed here. What community users and practitioners consistently report is that peptides, particularly BPC-157 and its common pairings, are useful for reducing inflammation, stopping bleeding, and relieving pain. Reversing existing recession, meaning actually regrowing gum tissue height, is a different goal and one that the dental consensus still considers to require surgical intervention such as connective tissue grafting. A small number of community reports describe partial regrowth, but these are individual accounts without controls, and most users describing significant recession do not report meaningful tissue gain.

What is the difference between treating inflammation and treating periodontal disease?

Periodontal disease involves two overlapping problems: active bacterial infection driving the inflammation, and the tissue and bone destruction that inflammation causes over time. Treating the inflammation, which is where most community peptide protocols focus, can meaningfully reduce symptoms and may slow disease progression. But it does not eliminate the underlying bacterial biofilm, which is what drives the process forward. The antimicrobial peptides higher on this list, AMY-101, KSL-W, and P-113, address the bacterial and immune dysregulation root of the disease more directly. A purely anti-inflammatory approach without addressing the microbial load is likely to require sustained use to maintain any benefit, because the source of the inflammation remains.

Do these peptides replace professional dental treatment?

No peptide in this guide replaces scaling and root planing, surgical intervention, or routine professional care. The compounds discussed here are used alongside standard periodontal treatment, not instead of it. Even AMY-101, which resolved inflammation without mechanical treatment in its trial, was studied over a short term in a controlled setting, and no evidence suggests it eliminates the need for long-term professional maintenance. For anyone managing active gum disease, professional treatment is the foundation, and any peptide protocol is an adjunct to that care, not a replacement.

Is it safe to inject peptides directly into gum tissue?

Some community users and at least one dentist have described injecting BPC-157 or related peptides near affected gum tissue, reporting stronger localized effects than other administration routes. This is not a clinically validated approach and carries real risks, including infection at the injection site, contamination from unregulated research chemicals, and the complete absence of safety data for this specific application. Research-chemical compounds used this way have not been tested to the sterility standards appropriate for injection near oral mucosa. Anyone considering this route should understand that they are operating well outside any studied or approved protocol.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for gum disease in one place.